To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors
Patients with histologically confirmed myeloid, B lymphocyte, and plasma cell-derived malignant hematological tumors.
Lymphocyte count ≤ 0.8×109/L or CD4+T cell count ≤ 0.35×109/L.
Age ≥ 18 years, both male and female, with an expected survival period of more than 3 months.
Estimated creatinine clearance rate ≥ 30 mL/min.
Active autoimmune disease.
Patients considered to have a malignant T-cell clone.
Within 8 days after chemotherapy for lymphoma and within 14 days after chemotherapy for AML.
Tumor involvement in the bone marrow leading to hematopoietic suppression (neutrophils <1.0×10^9/L, HB<70g/L, PLT<50×10^9/L).